Company Overview and News

0
Electrovaya Announces Initial and Follow-up Purchase Orders From Multiple Customers

2018-06-12 globenewswire
TORONTO, June 12, 2018 (GLOBE NEWSWIRE) -- Electrovaya Inc. (“Electrovaya” or the “Company”) (TSX:EFL) (OTCQX:EFLVF), today announced purchase orders totalling approximately US$1.8 million (~C$2.3 million) for its ELivate line of forklift battery systems and energy storage modules. Electrovaya received initial orders from two new customers, and follow-up purchase orders from several repeat customers.
EFL

0
Electrovaya Completes Private Placement

2018-05-30 globenewswire
Not for distribution in the United States newswire services or for dissemination in the United States
EFL

0
Electrovaya Announces Private Placement for Proceeds of up to $700,000

2018-05-16 globenewswire
Not for distribution in the United States newswire services or for dissemination in the United States
EFL

0
Electrovaya Announces Purchase Orders from Two Customers Through a Leading Lift Truck OEM Dealer

2018-05-04 globenewswire
TORONTO, May 04, 2018 (GLOBE NEWSWIRE) -- Electrovaya Inc. (“Electrovaya” or the “Company”) (TSX:EFL) (OTCQX:EFLVF), is pleased to announce purchase orders from two customers totalling $511,000 (Cdn ~$656,000) for its ELivate line of forklift battery systems.
EFL

0
Electrovaya Reports Financial Results for Q2 2018

2018-04-24 globenewswire
TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Electrovaya Inc. (“Electrovaya” or the “Company”) (TSX:EFL) (OTCQX:EFLVF) today reported its financial results for the fiscal second quarter ended March 31, 2018 (“Q2 2018”). All numbers are in U.S. dollars unless otherwise noted.
EFL

0
Electrovaya Announces Date of Earnings Release and Conference Call to Discuss the Quarter ended March 31, 2018 Financial Results

2018-04-23 globenewswire
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Electrovaya Inc. (TSX:EFL) (OTCQX:EFLVF) today announced that it will release the financial results for the quarter ended March 31, 2018 on Tuesday April 24th, 2018 after the markets close. CEO Dr. Sankar Das Gupta and EVP & CFO Richard Halka will host a conference call on Wednesday April 25th, 2018 at 8:00 a.m. Eastern Time (ET) to discuss the results and provide a business update.
EFL

0
Electrovaya Announces Results of Annual and Special Shareholders’ Meeting

2018-04-02 globenewswire
TORONTO, April 02, 2018 (GLOBE NEWSWIRE) -- Electrovaya Inc. (TSX:EFL) (OTCQX:EFLVF) (the “Company”) is pleased to announce that all of the resolutions that shareholders were asked to consider at its 2018 Annual and Special Meeting held on March 29th, 2018 in Mississauga, Ontario, were approved. The six directors named in the management information circular of the Company, being Dr. Sankar Das Gupta, Dr.
EFL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:EFL / Electrovaya Inc. on message board site Silicon Investor.

Firefly/Serenity Deflation
Reflect Scientific (medical, biotech u0026 transportation device Teleflex (TFX) a company which just grows and grows
EFLT - Elite Flight Solutions, Inc. Consumer Products Price Tracker (Inflation, Deflation)
Fly High w/ Bluefly.com (BFLY) !!! The next Amazon.com? Gold,monetary policy,inflation,deflation-no ufos,hate etc
BLUEFLY.COM(BFLY) Deflation: Highly Likely? UNPH ADRX BGEN SBTK TDFX Article